Recently, the 2025 Zhongguancun Forum Annual Conference concluded successfully. At the Permanent Exhibition in the Zhongguancun National Independent Innovation Demonstration Zone Exhibition Center, AccuMedical showcased its self-developed Lattice Flow Diverter and Lattice NEXT Flow Diverter with "Non-Extended Tip Guidewire" in the High-End Medical Device Exhibition Area. The innovations were prominently covered by major central media outlets, including CCTV-13 News Channel’s "News Live Room", CCTV-2 Finance Channel’s "Economic News" and "The First Time", as well as CCTV-4 Chinese International Channel’s "China News".
As China’s national platform for global exchange and cooperation in technological innovation, this year’s Forum was themed “New Quality Productive Forces and Global Technological Cooperation”, offering deep discussions on cutting-edge science and technology trends and industrial development, while exploring new pathways for fostering innovation-driven productivity to support global progress.
The Permanent Exhibition of the Zhongguancun Forum focused on global scientific frontiers and future industries, featuring over 490 exhibits from more than 350 organizations, including 130+ first-release projects. Highlights included breakthroughs in AI+, humanoid robotics, commercial aerospace, intelligent connected new-energy vehicles, synthetic bio-manufacturing, innovative drugs, and high-end medical devices. The exhibition comprehensively showcased Beijing’s latest achievements in using technological innovation to lead the development of new quality productive forces and build a modern industrial system.
During the Forum, AccuMedical made a strong appearance in the high-end medical device exhibition area with several of its innovative products. This marks the second consecutive year the company has participated in the Zhongguancun Forum, demonstrating its leading innovations driven by technology, and once again attracting key coverage by CCTV. The national spotlight on CCTV is a testament to the attention garnered by AccuMedical’s breakthrough products and a strong endorsement of its R&D capabilities.
As a technology-driven medical device company focusing on neurointervention, AccuMedical’s portfolio includes a comprehensive range of interventional and access-related innovative devices for the treatment of both hemorrhagic and ischemic stroke. The Lattice and Lattice NEXT devices, featured in the CCTV coverage, represent major industry innovations.
The Lattice Flow Diverter, approved via China’s Special Review Procedure for Innovative Medical Devices, is the first to extend the indications of flow diverters to the treatment of medium and small vertebral artery aneurysms, currently the broadest approved indication among similar products. Constructed with cobalt-chromium alloy, and equipped with globally first-in-class technologies such as a mechanical balloon delivery system and MIROR surface modification, Lattice fills several domestic technology gaps. In clinical performance, the Lattice demonstrated a 91.4% aneurysm occlusion rate at 12 months post-operation and an in-stent stenosis rate of just 0.8%, significantly outperforming comparable products.
Thanks to these breakthrough innovations, AccuMedical has effectively reduced the technical complexity of procedures for physicians, shortened surgery times, and improved both patient outcomes and procedural safety, marking the beginning of a new “automatic gear” era in intracranial aneurysm treatment. Lattice is now being used in multiple hospitals and has been highly praised by clinicians. With reduced procedural difficulty, its application has extended to rural and county-level hospitals, enabling more young doctors to confidently treat patients using this device—fulfilling real clinical needs.
Since its inception, AccuMedical has positioned technological innovation as its core competitive edge. To date, eight of its products—including Lattice and Lattice NEXT—have been approved by the NMPA, and the company has filed 132 patent applications, with 73 already granted. AccuMedical was recognized as a National High-Tech Enterprise in 2023, and selected as a National-level “Little Giant” Enterprise in 2024.
Joining this year's Zhongguancun Forum Permanent Exhibition alongside many other cutting-edge innovations further affirms AccuMedical’s strength in technological innovation. The enthusiasm surrounding the 2025 Zhongguancun Forum reflects how frontier technologies are accelerating toward real-world application and ecosystem development. AccuMedical’s products and solutions illustrate how China’s medical innovators are contributing new momentum to the fight against cerebrovascular diseases, and how new quality productive forces are enhancing the accessibility of innovative medical technologies.